Catalyst Pharmaceuticals, Inc. CPRX
Set alert
31.49 USD 0.00 0.00%
As of Jul 15, 9:30 AM ET
31.49 Day range 31.49
52-week range unavailable
- YTD
- +34.92%
- 1 year
- +43.86%
- Open
- 31.49
- Prev close
- 31.49
- Mkt cap
- 3.85B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.49
- High
- 31.49
- Beta
- 0.74
- Inst. own
- 90.00%
- Dividend
- 0.00
- Earnings
- Aug 5, 2026
Analyst view
Price target (mean) —
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 6
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.73589 | 0.73589 – 0.73589 | 0.68 | +8.2% | 154.55M | +5.5% | 1 |
| Next quarter | 0.81843 | 0.81843 – 0.81843 | 0.68 | +20.4% | 162.10M | +9.2% | 1 |
| Current year | 3.17 | 3.17 – 3.17 | 2.72 | +16.7% | 636.20M | +8.0% | 1 |
| Next year | 3.18 | 2.58 – 3.55 | 3.17 | +0.2% | 717.90M | +12.8% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 8, 2026 | Citigroup | Downgrade | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | Downgrade | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Nov 7, 2025 | Citigroup | Maintained | Buy | Buy |
| Mar 3, 2025 | Baird | Maintained | Outperform | Outperform |
| Feb 28, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 27, 2025 | Stephens & Co. | Reiterated | Overweight | Overweight |
| Feb 4, 2025 | Baird | Initiated | — | Outperform |
| Jan 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 9, 2025 | B of A Securities | Reiterated | Buy | Buy |
| Nov 18, 2024 | Stephens & Co. | Initiated | — | Overweight |
| Nov 11, 2024 | Truist Securities | Maintained | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 9, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 9, 2024 | Truist Securities | Maintained | Buy | Buy |
| Jun 6, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jun 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 27, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 22, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Mar 14, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Mar 14, 2024 | Citigroup | Initiated | — | Buy |
| Mar 7, 2024 | B of A Securities | Initiated | — | Buy |
| Mar 1, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Mar 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 21, 2023 | Oppenheimer | Initiated | — | Outperform |
| Aug 22, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 11, 2023 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
